Exscientia PLC
NASDAQ:EXAI

Watchlist Manager
Exscientia PLC Logo
Exscientia PLC
NASDAQ:EXAI
Watchlist
Price: 4.84 USD Market Closed
Market Cap: 633.2m USD
Have any thoughts about
Exscientia PLC?
Write Note

Exscientia PLC
Operating Expenses

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Exscientia PLC
Operating Expenses Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Expenses CAGR 3Y CAGR 5Y CAGR 10Y
Exscientia PLC
NASDAQ:EXAI
Operating Expenses
-ÂŁ167.1m
CAGR 3-Years
-91%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Operating Expenses
-$178.1m
CAGR 3-Years
-157%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Autolus Therapeutics PLC
NASDAQ:AUTL
Operating Expenses
-$177.2m
CAGR 3-Years
-1%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Operating Expenses
-$233.4m
CAGR 3-Years
-45%
CAGR 5-Years
-43%
CAGR 10-Years
N/A
Immunocore Holdings PLC
NASDAQ:IMCR
Operating Expenses
-ÂŁ308m
CAGR 3-Years
-37%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Operating Expenses
-ÂŁ614.6m
CAGR 3-Years
-6%
CAGR 5-Years
-36%
CAGR 10-Years
-6%
No Stocks Found

Exscientia PLC
Glance View

Market Cap
608.4m USD
Industry
Biotechnology

Exscientia Plc operates as an AI-driven pharmatech company which is engaged in designing and developing patient-based drugs. The company is headquartered in Oxford, Oxfordshire and currently employs 208 full-time employees. The company went IPO on 2021-10-01. The firm's focus is on the discovery, design and development of small molecule drug candidates. The firm has built a complete end-to-end solution of artificial intelligence (AI), and experimental technologies for target identification, drug candidate design, translational models and patient selection. Its AI process is comprised of the four elements: Precision Target, Precision Design, Precision Experiment and Precision Medicine. Its AI-design includes a range of deep learning and machine learning algorithms, generative methods, active learning and natural language processing. These methods are used to guide target selection, to design the precise molecular architecture of potential drug molecules and to analyze patient tissues to prioritize the molecules. The firm's lead drug candidate, EXS21546, is in early stage of development.

EXAI Intrinsic Value
4.74 USD
Overvaluation 2%
Intrinsic Value
Price

See Also

What is Exscientia PLC's Operating Expenses?
Operating Expenses
-167.1m GBP

Based on the financial report for Dec 31, 2023, Exscientia PLC's Operating Expenses amounts to -167.1m GBP.

What is Exscientia PLC's Operating Expenses growth rate?
Operating Expenses CAGR 3Y
-91%

Over the last year, the Operating Expenses growth was 16%. The average annual Operating Expenses growth rates for Exscientia PLC have been -91% over the past three years .

Back to Top